Emerging linezolid-resistant, vancomycin resistant Enterococcus faecium from a patient of a haematological unit in Poland

• Autorzy: Krawczyk B , Samet A. , Bronk M. , Hellmann A. , Kur J.
• Języki publikacji: EN

Abstrakty

EN

The oxazolidinone antimicrobial, linezolid, has been approved for the treatment of infections caused by various gram-positive bacteria, including vancomycin-resistant enterococci (VRE). This is the first report on isolation of a linezolid resistant, vancomycin-resistant Enterococcus faecium (LRVREF) strain in Poland, from a Haematological Unit patient in the Clinical Hospital in Gdańsk. PCR-RFLP analysis of rDNA and allele-specific PCR of the domain V region of the 23S ribosomal RNA gene demonstrated the presence of the G2576U mutation previously reported to be associated with linezolid resistance. Both assays detected heterozygous in this position.

Słowa kluczowe

EN

oxazolidinone; patient; Poland; new antibiotic; hematological unit; vancomycin resistant; Enterococcus faecium

• Wydawca: -
• Czasopismo: Polish Journal of Microbiology
• Rocznik: 2004
• Tom: 53
• Numer: 3
• Opis fizyczny: p.193-196,fig.,ref.

Twórcy

autor

Krawczyk B

• Gdansk University of Technology, G.Narutowicza 11-12, 80-952 Gdansk, Poland

autor

Samet A.

autor

Bronk M.

autor

Hellmann A.

autor

Kur J.

Bibliografia

• Gonzales R.D., P.C. Schreckenberger, M.B. Graham, S. Kelkar, K. Den Besten and J.P. Quinn. 2001. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357: 1179.
• Herrero I.A., N.C. Issa and R. Patel. 2002. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N. Engl. J. Med. 346: 867-869.
• Jones R.N., P. Della-Latta, L.V. Lee and D.J. Biedenbach. 2002. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 42: 137.
• Kloss P., L. Xiong, D.L. Shinabarger and A.S. Mankin. 1999. Resistance mutations in 23S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J. Mol. Biol. 294: 93-101.
• Livermore D.M. 2000. Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? J. Antimicrob. Chemother. 46: 347-350.
• Prystowsky J., F. Siddiqui, J. Chosay, D.L. Shinabarger, J. Millichap, L.R. Peterson and G.A. Noskin. 2001. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 45: 2154-2156.
• Tsiodras S., H.S. Gold, G. Sakoulas, G.M. Eliopoulos, C. Wennersten, L. Venkataraman, R.C.Moellering and M J. Ferraro. 2001. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358: 207-208.
• Zurenko G., W.M. Todd, B.A. Hafkin, B. Myers, C. Kaufman and J. Bock. 1999. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid [abstract 848], p. 118. In: Program and abstracts of the 39th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). American Society for Microbiology, Washington, DC.